UNSPSC 51181603: Liotrix

This classification denotes a thyroid hormone and thyroxine-triiodothyronine drug combination with the molecular formula C30H23I7N2O8, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier YW8HJ0N26X, more generally known as liotrix, chemically known as (2S)-2-amino-3-[4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl]propanoic acid;(2S)-2-amino-3-[4-(4-hydroxy-3-iodophenoxy)-3, 5-diiodophenyl]propanoic acid, but generally known as liotrix. As of Q4 2014, LIOTRIX remains the US FDA Preferred Term for this commodity.

Liotrix bears US NLM identifiers UMLS ID C0936106 and NCI Concept Code C87251. SMILES: C1=CC(=C(C=C1OC2=C(C=C(C=C2I)CC(C(=O)O)N)I)I)O.C1=C(C=C(C(=C1I)OC2=CC(=C(C(=C2)I)O)I)I)CC(C(=O)O)N.

UNSPSC 51181603 Liotrix is a Commodity code covering synthetic thyroid hormone replacement products. State and local governments procure liotrix and similar combination thyroid medications through cooperative purchasing agreements and direct pharmaceutical supply contracts to support Medicaid, state employee health plans, correctional health services, and local public health clinics. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, dominates recent activity in this space, using cooperative vehicles to aggregate demand across multiple states and local jurisdictions. Solicitations under this code require vendors to meet cGMP and Drug Supply Chain Security Act (DSCSA) compliance, maintain relationships with authorized pharmaceutical wholesalers (typically AmerisourceBergen/Cencora, Cardinal Health, and Morris & Dickson), and provide detailed product information including National Drug Codes, SKUs, and UPCs. Insurance requirements typically include commercial general liability coverage of $5,000,000 per occurrence and network security and privacy liability of $2,000,000 or greater.

MMCAP's January 2026 RFP for generic multi-source pharmaceuticals and OTC products (S1070000015802, due March 26, 2026) represents the most recent solicitation under this code. The cooperative agreement spans Minnesota and Oregon and establishes contracts effective July 1, 2026, with a two-year initial term for new vendors and optional extensions through June 30, 2028 for incumbents. Evaluation is weighted heavily toward price competitiveness (75 percent) and compliance with administrative and EDI requirements (15 percent combined), with fixed pricing and agreement to a 3 percent administrative fee comprising the remaining 10 percent. Vendors must demonstrate pricing flexibility through flat-price, net-price, or WAC-minus formats and maintain inventory availability with minimum six-month shelf life. Performance penalties range from $200 to $1,500 per violation for late reporting, missed timelines, or class-of-trade denials.